Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -162.00K | 0.00 | -292.00K | -291.00K | -296.00K | -277.00K |
EBITDA | -172.21M | -109.52M | -100.83M | -70.36M | -55.39M | -42.66M |
Net Income | -128.24M | -109.96M | -85.89M | -67.38M | -54.00M | -36.05M |
Balance Sheet | ||||||
Total Assets | 866.99M | 908.32M | 368.49M | 168.53M | 210.66M | 256.50M |
Cash, Cash Equivalents and Short-Term Investments | 851.86M | 902.61M | 362.08M | 155.49M | 202.10M | 248.39M |
Total Debt | 1.00M | 1.12M | 1.26M | 1.56M | 29.00K | 359.00K |
Total Liabilities | 20.07M | 28.04M | 20.07M | 23.21M | 8.78M | 12.16M |
Stockholders Equity | 846.92M | 880.28M | 348.42M | 145.32M | 201.88M | 244.34M |
Cash Flow | ||||||
Free Cash Flow | -133.99M | -87.79M | -73.38M | -48.40M | -47.59M | -21.78M |
Operating Cash Flow | -133.99M | -87.79M | -73.38M | -48.40M | -47.59M | -21.78M |
Investing Cash Flow | -30.33M | -553.37M | -179.09M | 54.75M | 37.96M | 41.57M |
Financing Cash Flow | 6.78M | 612.46M | 271.38M | 4.16M | 6.88M | 950.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $3.55B | 15.46 | 37.24% | ― | 22.42% | ― | |
64 Neutral | ¥343.76B | 10.59 | -2.88% | 2.57% | 11.81% | -7.17% | |
53 Neutral | $3.11B | ― | -14.40% | ― | ― | -23.84% | |
53 Neutral | $2.24B | ― | -103.82% | ― | 48.04% | 48.16% | |
51 Neutral | $2.76B | ― | -30.84% | ― | ― | -1.20% | |
50 Neutral | $3.38B | ― | -106.71% | ― | ― | -22.34% | |
45 Neutral | $2.87B | ― | -62.46% | ― | ― | -43.10% |
Viking Therapeutics has presented promising data from its VK2735 obesity program at ObesityWeek® 2024, showcasing up to 8.2% weight loss from baseline with an oral formulation over 28 days. The treatment demonstrated strong tolerability, with mild GI-related side effects, and the potential for longer-term weight loss. These findings are significant for those exploring innovative solutions in metabolic disorder treatments, with both oral and subcutaneous forms of VK2735 showing durable effects.